Effect of silodosin, an alpha1a-adrenoceptor antagonist, on benign prostatic hyperplasia in rat
10.3760/cma.j.issn.1008-1372.2016.02.011
- VernacularTitle:α1a肾上腺素受体拮抗剂西洛多辛对大鼠良性前列腺增生的影响
- Author:
Bing LIU
;
Zhifeng PENG
- Publication Type:Journal Article
- Keywords:
Adrenergic beta-antagonists/PD;
Testosterone/AE;
Prostatic hyperplasia/ET/DT
- From:
Journal of Chinese Physician
2016;18(2):199-202,207
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of silodosin,a selective alpha1 a-adrenoceptor antagonist on a rat model of testosterone-induced benign prostatic hyperplasia (BPH) and its mechanisms.Methods The rats were divided into three groups:control,testosterone-induced BPH,and silodosin +BPH groups.BPH was induced by subcutaneous injection of testosterone [20 mg/(kg · d)] for 4 weeks.Meanwhile silodosin + BPH groups rats were administered silodosin 4 weeks [100 μg/(kg · d)].After 4 weeks,all animals were sacrificed to examine the blood biochemical profiles,prostate volume,weight,histopathological changes,and epidermal growth factor receptor (EGFR) and B-cell chronic lymphocytic leukemia (CLL)/lymphoma 2 (BCL-2) protein expressions.Results Each group showed an increase compared to their initial body weight;however,differences in weight change between groups were not significant (P ＞ 0.05).The BPH group displayed lower glucose levels than the control group.The serum levels of glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT) were not significantly different among groups (P ＞ 0.05).The group treated with silodosin showed significantly lesser prostate size and weight than the testosterone-induced BPH group [volume:(0.93 ± 0.14) cm3 vs (1.75 ± 0.15)cm3,P ＜0.01;weight:(0.97 ±0.06)g vs (1.30±0.05)g,P ＜0.01].In addition,silodosin decreased the expressions of EGFR and BCL-2 in prostate tissues (P ＜ 0.05).Conclusions These results suggest that silodosin suppress the development of BPH by inhibiting the expressions of EGFR and BCL-2.
